Meditsinskiy Sovet · Sep 21, 2026
Efficacy and safety of tirzepatide in the treatment of obesity and obesity-associated comorbidities
By Sakhnova EE, Gavrilova NA, Ostroumova OD et al.
The aim of this publication is to demonstrate the efficacy of tirzepatide in a patient with obesity and obesity-associated comorbidities in a real-world clinical setting. A case report of a 36-year-old patient with obesity, arterial hypertension, impaired glucose tolerance, dyslipidemia, hyperuricemia, and metabolic dysfunction-associated steatotic liver disease is presented. At baseline, body weight was 126 kg, body mass index was 38 kg/m2, and waist circumference was 117 cm. The patient was recommended lifestyle modification and treatment with tirzepatide, with gradual dose escalation to 12.5 mg once weekly. After 15 months of therapy, body weight decreased to 91 kg (-27.8%), body mass index to 27.8 kg/m2, and waist circumference to 94 cm. Body composition analysis demonstrated a reduction in adipose tissue mass with preservation of skeletal muscle mass. Normalization of blood levels of glucose, lipids, uric acid, and blood pressure parameters was achieved during treatment. Echocardiography demonstrated a reduction in epicardial adipose tissue thickness. No clinically significant adverse events were observed throughout the treatment period. Tirzepatide may provide clinically meaningful benefits in the treatment of obesity in patients with cardiometabolic disorders. Its use is associated with substantial weight loss, improvement in glycemic control, lipid profile, and uric acid levels, as well as lower cardiovascular risk. Of particular interest is the reduction in adipose tissue mass while preserving skeletal muscle mass. Tirzepatide has shown multifaceted metabolic effects, along with manageable adverse profiles, which makes it a promising therapeutic agent for addressing obesity and associated comorbidities.